DNA-damage response-umbrella study of the combination of ceralasertib and olaparib, or ceralasertib and durvalumab in advanced biliary tract cancer: A phase 2 trial-in-progress.

被引：3
|
作者：
Yoon, Jee Sun
Kim, Jin Won
Kim, Ji-Won
Kim, Tae-Yong
Nam, Ah-Rong
Bang, Ju-Hee
Seo, Hye-Rim
Kim, Jae-Min
Oh, Kyoung Seok
Mortimer, Peter G.
Smith, Simon
Oh, Do-Youn
机构：
[1] Seoul Natl Univ, Seoul Natl Univ Hosp, Coll Med, Dept Internal Med, Seoul, South Korea
[2] Seoul Natl Univ, Bundang Hosp, Coll Med, Dept Internal Med, Seongnam, South Korea
[3] Seoul Natl Univ, Coll Med, Canc Res Inst, Seoul, South Korea
[4] AstraZeneca, R&D Oncol, Early Oncol Clin Sci, Cambridge, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.TPS4166
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS4166
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Trial in progress: A phase II open-label, randomized study of PARP inhibition (olaparib) either alone or in combination with anti-PD-L1 therapy (atezolizumab) in homologous DNA repair (HDR) deficient, locally advanced or metastatic non-HER2-positive breast cancer.
    LoRusso, Patricia
    Pilat, Mary Josephine Paula
    Santa-Maria, Cesar Augusto
    Connolly, Roisin M.
    Roesch, Erin Elizabeth
    Afghahi, Anosheh
    Han, Hyo S.
    Nanda, Rita
    Wulf, Gerburg M.
    Assad, Hadeel
    Park, Haeseong
    Dees, Elizabeth Claire
    Force, Jeremy Meyer
    Noonan, Anne M.
    Brufsky, Adam
    Abramson, Vandana G.
    Haley, Barbara B.
    Buys, Saundra S.
    Sharon, Elad
    Schalper, Kurt A.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [32] CTX-009 (ABL001), a bispecific antibody targeting DLL4 and VEGF A, in combination with paclitaxel in patients with advanced biliary tract cancer (BTC): A phase 2 study.
    Oh, Do-Youn
    Park, Joon Oh
    Kim, Jin Won
    Kim, Kyu-Pyo
    Yoon, Jeesun
    Kim, Tae-Yong
    Kim, Seung Tae
    Park, Young Suk
    Lee, Jeeyun
    Kim, Ji-Won
    Lee, Keun-Wook
    Ryoo, Baek-Yeol
    Yoo, Changhoon
    Hyun, BokJin
    Son, HyunJoo
    Kim, SunYoung
    Lee, SangMi
    Park, Jooyeon
    Ha, Eunsin
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 540 - 540
  • [33] Randomized phase II trial of gemcitabine plus S-1 combination therapy versus S-1 in advanced biliary tract cancer: Results of the Japan Clinical Oncology Group study (JCOG0805)
    Ueno, Makoto
    Okusaka, Takuji
    Mizusawa, Junki
    Takashima, Atsuo
    Morizane, Chigusa
    Ikeda, Masafumi
    Hamamoto, Yasuo
    Ishii, Hiroshi
    Hara, Hiroki
    Fukutomi, Akira
    Furukawa, Masayuki
    Nagase, Michitaka
    Yamaguchi, Taketo
    Yamao, Kenji
    Nakamori, Shoji
    Ioka, Tatsuya
    Iguchi, Haruo
    Miyakawa, Hiroyuki
    Boku, Narikazu
    Furuse, Junji
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [34] Randomized phase II trial of gemcitabine plus S-1 combination therapy versus S-1 in advanced biliary tract cancer: Results of the Japan Clinical Oncology Group study (JCOG0805)
    Morizane, Chigusa
    Okusaka, Takuji
    Mizusawa, Junki
    Takashima, Atsuo
    Ueno, Makoto
    Ikeda, Masafumi
    Hamamoto, Yasuo
    Ishii, Hiroshi
    Boku, Narikazu
    Furuse, Junji
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
  • [35] RANDOMIZED PHASE II TRIAL OF GEMCITABINE PLUS S-1 COMBINATION THERAPY VERSUS S-1 IN ADVANCED BILIARY TRACT CANCER: RESULTS OF THE JAPAN CLINICAL ONCOLOGY GROUP STUDY (JCOG0805)
    Ikeda, M.
    Okusaka, T.
    Mizusawa, J.
    Takashima, A.
    Morizane, C.
    Ueno, M.
    Hamamoto, Y.
    Ishii, H.
    Hara, H.
    Fukutomi, A.
    Furukawa, M.
    Nagase, M.
    Yamaguchi, T.
    Boku, N.
    Furuse, J.
    ANNALS OF ONCOLOGY, 2012, 23 : 15 - 15
  • [36] Nab-paclitaxel plus anti-PD-1 antibody as second-line treatment for advanced biliary tract cancer: An investigator-initiated phase 2 study (NapaSinti trial).
    Li, Xiaofen
    Zhou, Nan
    Yang, Yu
    Gou, Hongfeng
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 564 - 564
  • [37] Trial in progress: A phase 2/3 randomized, controlled study of CTX-009 in combination with paclitaxel versus paclitaxel alone in adult patients with unresectable advanced, metastatic or recurrent biliary tract cancers who have received one prior systemic chemotherapy regimen.
    Fontaine, Marilyn
    Pilgrim, Sarah
    Schuetz, Thomas
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : TPS640 - TPS640
  • [38] ONCX-NAV-G201: A phase 2 basket study of navicixizumab monotherapy or in combination with chemotherapy in patients with select advanced solid tumors-Colorectal Cancer Cohort (trial in progress).
    Oberstein, Paul Eliezer
    Pelster, Meredith
    Culm, Kerry
    Santos, Valerie Chamberlain
    Koustenis, Andrew
    Mockbee, Colleen M.
    Youssoufian, Hagop
    Krauss, John C.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : TPS263 - TPS263
  • [39] IMbrave151: A phase 2, randomized, double-blind, placebo-controlled study of atezolizumab with or without bevacizumab in combination with cisplatin plus gemcitabine in patients with untreated, advanced biliary tract cancer.
    El-Khoueiry, Anthony B.
    Ren, Zhenggang
    Chon, Hongjae
    Park, Joon Oh
    Kim, Jin Won
    Pressiani, Tiziana
    Li, Daneng
    Zhukova, Lyudmila
    Chen, Ming-Huang
    Hack, Stephen Paul
    Wu, Stephanie
    Liu, Bo
    Wang, Yulei
    Macarulla, Teresa
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 491 - 491
  • [40] A phase II clinical trial to analyze olaparib response in patients with BRCA1 and/or BRCA2 promoter methylation with advanced breast cancer (GEICAM/2015-06 COMETA-Breast study).
    De La Haba, Juan
    Guerrero-Zotano, Angel
    Alejandro Perez-Fidalgo, Jose
    Gonzalez Santiago, Santiago
    Munoz, Montserrat
    Andres, Raquel
    Cruz Zambrano, Cristina
    Moran Salama, Sebastian
    Lopez-Tarruella, Sara
    Quiroga Garcia, Vanesa
    Servitja, Sonia
    Mele, Mireia
    Alonso Soler, Sonia
    Adamo, Barbara
    Jose Escudero, Maria
    Martin, Nuria
    Bezares, Susana
    Caballero, Rosalia
    Esteller, Manel
    Rojo, Federico
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
12345